The microbiome in recurrent pregnancy loss - A scoping review.

Endometrium Microbiome Microbiota Miscarriage Pregnancy loss Vagina

Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
25 Apr 2024
Historique:
received: 26 07 2023
revised: 23 12 2023
accepted: 22 04 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: aheadofprint

Résumé

Recurrent pregnancy loss (RPL) is a troubling condition that affects couples worldwide. Despite extensive research efforts, many RPL cases remain unexplained, highlighting the need for novel approaches to unravel its underlying mechanisms. Recent advances in microbiome research have shed light on the potential role of the microbiome in reproductive health and outcomes. Based on a systematic literature research, this review aims to comprehensively explore the current understanding of the microbiome's involvement in RPL, focusing on the vaginal, endometrial, and gut microbiomes. Evidence from the available studies is examined to explain the relationship between the microbiome and RPL. Furthermore, we discuss the diagnostic potential of the microbiome, therapeutic interventions, and future directions in microbiome research for RPL. Understanding the complex interactions between the microbiome and reproductive health holds promise for developing targeted interventions to help patients today diagnosed as unexplained.

Identifiants

pubmed: 38718429
pii: S0165-0378(24)00060-3
doi: 10.1016/j.jri.2024.104251
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104251

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Kilian Vomstein received speaker’s fees from Merck Denmark A/S, Gedeon Richter, IBSA Nordic and support for travel to conferences from Ferring Pharmaceuticals. Henriette Svarre Nielsen has received scientific grants from Freya Biosciences, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordisk Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, and Ole Kirks Fond. She received personal payment or honoraria for lectures and presentations from Ferring Pharmaceuticals, Merck, Astra Zeneca, Cook Medical, and IBSA Nordic. Tine Wrønding received speaker’s fees from Gedeon Richter. Maria C Krog has nothing to disclose.

Auteurs

Kilian Vomstein (K)

The Recurrent Pregnancy Loss Unit, The Capital Region, Copenhagen University Hospitals, Hvidovre Hospital, Hvidovre & Rigshospitalet, Copenhagen DK-2650, Denmark; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, DK-2650, Denmark. Electronic address: thomas.kilian.vomstein@regionh.dk.

Maria C Krog (MC)

The Recurrent Pregnancy Loss Unit, The Capital Region, Copenhagen University Hospitals, Hvidovre Hospital, Hvidovre & Rigshospitalet, Copenhagen DK-2650, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2100, Denmark.

Tine Wrønding (T)

The Recurrent Pregnancy Loss Unit, The Capital Region, Copenhagen University Hospitals, Hvidovre Hospital, Hvidovre & Rigshospitalet, Copenhagen DK-2650, Denmark; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, DK-2650, Denmark.

Henriette Svarre Nielsen (HS)

The Recurrent Pregnancy Loss Unit, The Capital Region, Copenhagen University Hospitals, Hvidovre Hospital, Hvidovre & Rigshospitalet, Copenhagen DK-2650, Denmark; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, DK-2650, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.

Classifications MeSH